Active Biotech in Brief

Active Biotech develops pharmaceutical products within medical areas where the immune system is of significant importance, including cancer and inflammatory diseases. The project portfolio comprises both small, orally active immunomodulatory molecules and antibody-based immunotherapy.

Active Biotech has its base in Lund, Sweden and was formed in 1998 as a spin-off from Pharmacia & Upjohn. The share is listed and traded on Nasdaq Stockholm (Small Cap). The Company has core competence in cancer and inflammatory diseases and a competent team with extensive experience in drug development from early to late stage clinical development.

Beginning of 2020, new direction for the company was announced and the project portfolio is now composed of:

• Tasquinimod is in clinical development for hematological malignances. A phase Ib/IIa study of tasquinimod in relapsed refractory multiple myeloma is ongoing
• Laquinimod is in clinical development for inflammatory eye disorders. A phase I clinical study with a proprietary developed eye drop formulation of laquinimod is ongoing
• Naptumomab estafenatox (Naptumomab), licensed to NeoTX Therapeutics Ltd., is in clinical development for treatment of solid tumors. A phase II a study in non-small cell lung cancer (NSCLC) and a phase Ib/II study in selected solid tumors are ongoing